Dublin, Ireland – 4 September 2019 – GC Aesthetics (GCA), a global medical technology company with over 40 years of experience, is pleased to announce that it has become a Gold Sponsor of the International Society of Aesthetic Plastic Surgery (ISAPS).
GCA is committed to supporting surgeons in their professional development, whether through continuous training and networking activities at ISAPS events and workshops, or through our own GCA Academy, a digital training platform that hosts a range of live surgeries, webinars, and lectures sharing best practice.
“GC Aesthetics is proud to become a gold sponsor at ISAPS. As a global market leader with over 40 years of experience in medical aesthetics for women, we believe passionately in encouraging innovation and education that ensure the best outcomes for patients and surgeons. Working closely with ISAPS allows to combine our expertise in providing best-in class training to plastic surgeons around the world,”
said Carlos Reis Pinto, Chief Executive Officer of GC Aesthetics. Dr. Dirk Richter, President of ISAPS, added:
“I’m welcoming GC Aesthetics as selected ISAPS Global Gold Sponsor and looking forward to a fruitful cooperation.”
ISAPS is the world’s leading professional body for board-certified aesthetic plastic surgeons. Founded in 1970, ISAPS membership includes the world’s best known and respected reconstructive and aesthetic plastic surgeons in over 100 countries on every continent, reflecting the true international mission of the organization.
About GC Aesthetics
GC Aesthetics (GCA) is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal journey. Throughout 40 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality products under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. More than 3 million women and men across 70 countries have trusted GCA products, which are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness. The Company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.